Table 2.

Sterile inflammatory rates between anti-VEGF agents.

Study	Anti-VEGF agent	Number of patients	Number of injections	Percentage (%) of inflammation
Chong et al. (2010) [11]	Bevacizumab	—	16116	0.40%
Georgopoulos et al. (2009) [25]	Bevacizumab	—	2500	0.03%
Shima et al. (2008) [16]	Bevacizumab	707	1300	0.28%
Wickremasinghe et al. (2008) [10]	Bevacizumab	—	1278	1.49%
Johnson et al. (2010) [26]	Bevacizumab	173	693	1.30%
Sato et al. (2010) [22]	Bevacizumab	35	35	14.3%
Yamashiro et al. (2010) [19]	Bevacizumab	15	20	73%
Wang et al. (2013) [24]	Bevacizumab	116	116	69%
Wu et al. (2008) [27]	Bevacizumab	1173	4303	0.09%
Chong et al. (2010) [11]	Ranibizumab	—	3839	0.03%
Regillo et al. (2008) [28]	Ranibizumab	184	—	0%
Holz et al. (2011) [29]	Ranibizumab	514	—	0%
Busbee et al. (2013) [30]	Ranibizumab	1098	—	0.4%
Rosenfeld et al. (2006) [12]	Ranibizumab	716	—	2.6%
Brown et al. (2006) [13]	Ranibizumab	280	—	0.35%
Heier et al. (2006) [31]	Ranibizumab	105	—	11.4%
Antoszyk et al. (2008) [32]	Ranibizumab	105	—	9.5%
Rosenfeld et al. (2006) [18]	Ranibizumab	29	—	86%
Chun et al. (2006) [33]	Ranibizumab	10	30	50%
Chakravarthy et al. (2012) [34]	Bevacizumab and ranibizumab	610	—	0.16%
Ladas et al. (2009) [35]	Bevacizumab and ranibizumab	450	2000	1.90%
Sharma et al. (2012) [36]	Bevacizumab and ranibizumab	524	1584	1.90%
Hahn et al. (2013) [37]	Aflibercept	—	30000	0.05%
Ho et al. (2013) [38]	Aflibercept	85	—	0%
D'Amico et al. (2006) [39]	Pegaptanib	1190	—	0%
Singerman et al. (2008) [40]	Pegaptanib	161	1254	9%